子供への遺伝子ワクチン接種について、ご自身でも調べてみて、判断材料の一つの参考になればと思います。
日本感染症学会
COVID-19ワクチンに関する提言
「COVID-19ワクチンに関する提言（第5版）修正版」
グリーンブックのP24-25
Children aged 5-11 years1
Children at higher risk of severe COVID-19
Children and young people aged 5 to 11 years who are in recognised risk groups (table 4) should receive two doses of the paediatric dose (10 micrograms) of Pfizer BioNTech vaccine at an interval of at least eight weeks. Children in these risk groups will continue to become eligible when they turn 5 years of age, as will those aged 5-11 years who become at risk. Those with severe immunosuppression (box 2) will be eligible for a three dose primary course. Children in this group will also be eligible for a booster dose in the autumn programme (see section on the autumn programme).
Children aged 5-11 years who are contacts of immunosuppressed individuals Individuals aged 5-11 years who expect to share living accommodation on most days (and therefore for whom continuing close contact is unavoidable) with individuals of any age
who are immunosuppressed (defined as immunosuppressed in tables 3 or 4) should be
offered two doses of the paediatric dose (10 micrograms) of Pfizer BioNTech vaccine at an interval of at least eight weeks. Children in this groups will continue to become eligible when they turn 5 years of age, as will those aged 5-11 years when a close contact becomes immunosuppressed. Children in this group will also be eligible for a booster dose in the autumn programme (see section on the autumn programme).
Other children aged 5-11 years
In February 2022, the JCVI advised a one-off, non-urgent programme to offer vaccination to all children aged five to 11 years of age who are not in a clinical risk group. The immediate benefits of vaccination in this age group are likely to be small because children are at low risk
1 Including some children aged 12 years - see section on age specific recommendations on vaccine type
from COVID-19 infection, and by February 2022 almost all children in this age group will already have been infected with COVID-19. Although Omicron infection appears to be particularly mild, and the vaccine induced protection against mild Omicron infection is short lived, the offer is intended to increase and broaden protection against severe COVID-19 in advance of a potential future wave of COVID-19. As this offer is non-urgent, JCVI has recommended that delivery of paediatric non-COVID-19 immunisation programmes across all ages should receive due attention. Coverage in these other programmes has fallen behind during the pandemic, and may thus be increasing health inequalities, so it is important that COVID-19 vaccination does not further impact on these programmes.
Two doses of the paediatric vaccine (see the section on age specific recommendations on vaccine type) should be offered with an interval of at least 12 weeks between doses. This one-off programme applies to those aged 5 to 11 years, including those who turn five years of age before the end of August 2022. Subject to further clarification, on-going eligibility in 2022/23, after the one off-programme, is expected to be for children in the academic years where children are aged 11 or 12 years. Use of the paediatric formulation is advised for commencing (and for completing) vaccination for children in the relevant academic year.
